Home / Advocacy



The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology.  AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals. 

Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas. We invite you to explore AMP's Position Statements and Letters. For more information, please contact Mary Williams.

View all AMP Position Statements and Letters

Just released:

Comments to FDA regarding potential regulation of NGS Diagnostic Tests.


A Molecular Diagnostic Perfect Storm White Paper - addressing the Convergence of Regulatory and Reimbursement Forces that Threaten Patient Care.


Updates on Laboratory Developed Procedures (LDPs)


View AMP's written comments to FDA on LDPs


Signs from the 2014 Annual Meeting:  Are you ready to be a "manufacturer"?


FDA's website devoted to all information relevant to the draft framework: